SCHEMBL23933135

SCHEMBL23933135

Cc1ccc(S(=O)(=O)NN=CC23CC(OC(N)=O)(C2)C3)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.47
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
ALDH1A1 P00352 9/20 0.43
KMT2A Q03164 10/20 0.43
MEN1 O00255 8/20 0.43
MAPT P10636 4/20 0.41
LMNA P02545 2/20 0.41
POLB P06746 2/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 2/20 0.40
RBM39 Q14498 1/20 0.40
ALOX12 P18054 1/20 0.39
HTT P42858 1/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP1A2 P05177 1/20 0.39
CRHBP P24387 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23933134 1.00 F2 (0.47) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL23933112 0.81 KMT2A (0.47) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL23933111 0.81 KMT2A (0.47) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL30184806 0.79 KMT2A (0.49) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL29768849 0.79 ALDH1A1 (0.46) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL29768886 0.77 ALDH1A1 (0.43) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL29843445 0.70 KMT2A (0.49) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL31736490 0.70 MEN1 (0.49) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL26388343 0.70 ALDH1A1 (0.45) F2PRSS1PRSS2PRSS3ALDH1A1
SCHEMBL23172046 0.68 ALDH1A1 (0.56) F2PRSS1PRSS2PRSS3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4271387-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF Immunext, Inc. (US) 2023-11-08 EP disclosed
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 US disclosed
EP-4136118-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF Immunext, Inc. (US) 2023-02-22 EP disclosed
WO-2022150637-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF IMMUNEXT, INC. (US) 2022-07-14 WO disclosed
WO-2021216913-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT, INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF CD47, CLTA, FCGR2A F2 4875/4885PRSS1 2851/4885PRSS2 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.